Showing: 1 - 2 of 2 RESULTS

Vitalyc Medspa Acquires Unit Skin Studio

The Dallas Medspa Offers Non-Invasive Solutions for the FACE, BODY, & SKIN

Vitalyc Medspa, located at 6915 Preston Road in Dallas, has acquired Unit Skin Studio. The acquisition will absorb the Unit Skin Studio’s staff and clients into Vitalyc‘s Flagship location in University Park. Vitalyc offers solutions to help people age on their own terms using the latest non-invasive aesthetic treatments for both women and men.

Founder & CEO Amir Mortazavi created Vitalyc to provide both men and women with a direct path to anti-aging and has plans to open 25 locations in the next 5 years. While most of those will be new builds, Mortazavi affirms there are plenty of opportunities to acquire well-established business-like Unit Skin Studio and either rebrand or fold them into existing Vitalyc locations. Vitalyc blends the best treatment technology with the top aesthetic professionals to produce lasting results creating an UBER-like experience for consumers. Vitalyc uses app-based technology allowing clients to schedule appointments, monitor treatment progress, and check out using a contactless mobile experience.

“Our goal from the beginning was to provide our clients with an elevated experience which includes the latest technology and a dedicated team of experts,” says Unit Skin Studio Founder Lindsey Pinyero. “We are proud to transition our Unit family to Vitalyc to continue on their aesthetic journey and defy aging. Our passion has always been focused on service, experience, and results, Vitalyc delivers on all levels making the transition for our team simple!”

“We are committed to being good stewards of the businesses people put blood, sweat, and tears into,” says Mortazavi. “We believe through our technology, customer experience, and clinical excellence we can carry the torch for decades to come and are always looking for opportunities in Texas’s major suburban markets.”

The clinical team lead by facial plastic surgeon Demetri Arnaoutakis & Richard Moleno, took two years to curate the best equipment to treat conditions including unwanted fat, acne, enlarged pores, wrinkles, sagging skin, poor muscle definition, sun damage, volume loss, hormone imbalance, and dehydration.

“Our mission is restore confidence and defy aging,” says Mortazavi, whose state of the art treatment center boasts eight specialized rooms and a welcoming atmosphere whether you are a millennial or baby boomer.

To book your appointment, visit www.vitalyc.com or call (972) 994-9700.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005215/en/

Contacts

Allie Lesiuk
[email protected]
817-733-3766

Source Article

Fosun unit to begin U.S. trial of COVID-19 antibody treatment soon

BEIJING (Reuters) – China’s Shanghai Fosun Pharmaceutical Group said on Thursday an experimental antibody treatment for COVID-19 being developed by its unit had been approved for human testing in the United States and the trial was expected to start soon.

Several drugmakers are testing antibody treatments for COVID-19 to help patients’ immune systems fight the coronavirus that causes the disease which has killed over 1 million people worldwide.

Health experts say such antibody treatments could be used as a therapeutic bridge until vaccines become widely available.

Fosun said its unit, Hengenix Biotech Inc, planned to start an early stage clinical trial in the United States “in the near future after conditions are ready.”

Hengenix’s HLX70, a monoclonal neutralising antibody treatment, has obtained a clinical trial approval from U.S. Food and Drug Administration (FDA) to treat COVID-19 and acute respiratory distress syndrome (ARDS), or multiple organ failure caused by the virus, Fosun’s subsidiary Shanghai Henlius Biotech said earlier this week.

Fosun said it had invested about 15.2 million yuan ($2.2 million) in the research and development of HLX70 as of August.

No antibody treatments for COVID-19 have yet received an emergency use authorization (EUA) in the United States to fast-track them through the regulatory process. However, Regeneron Pharmaceuticals Inc said on Wednesday it had submitted a request for an EUA for its antibody combination, which was given to U.S. President Donald Trump to treat his infection.

Eli Lilly also said on Wednesday it had applied for an EUA for its experimental COVID-19 antibody treatment and planned to pursue a similar approval for a dual antibody therapy next month.

Fosun joins other Chinese developers in the antibody race, which include I-MAB and Shanghai Junshi Biosciences.

I-MAB has been cleared by the U.S. FDA to run a clinical trial for its antibody treatment TJM2 to treat Cytokine Release Syndrome associated with severe COVID-19, while JS016, a potential antibody treatment developed by Shanghai Junshi and licensed to Eli Lilly, is also being tested in the United States.

($1 = 6.7898 Chinese yuan renminbi)

(Reporting by Roxanne Liu and Tony Munroe; Editing by Mark Potter,)

Source Article